The company's development direction is set in the field of preventive medicine and precision medicine, which will grow substantially. Among them, "new drug development", "long-term care for the elderly" and "probiotic supplementary health products" are the main goals of the company's future development. We will work closely with medical units and academic units to achieve industrial innovation and improve the added value of products. Promote the combination of the company's research and development and performance, so that the company can develop sustainably.

In July 2015, SunIn Biotech Co., Ltd. was established and settled in the Southern Taiwan Science Park.

In September 2015, a strain isolation platform and a strain identification and analysis platform were established.

In April 2016, the cell culture room of SunIn Biotech Co., Ltd. was established.

In May 2016, a platform for the analysis and screening of immunomodulatory lactic acid strains was established.

In July 2016, the bacterial strain database of SunIn Biotech Co., Ltd. was established.

In October 2016, a screening platform for lactic acid bacteria to promote cell secretion of serotonin was established.

In April 2017 Established a screening platform for probiotics suitable for individuals.

In June 2017, a platform for the screening of the efficacy of lactic acid bacteria in regulating metabolic syndrome.

In August 2017, MedM probiotic capsule products and MedA probiotic capsule products were produced.

In November 2017, MedD probiotic capsule products and MedW probiotic capsule products were produced.

In January 2018, the animal experiment of L. acidophilus MB16 regulating blood sugar and blood lipids was completed.

December 2019 Patent application for "Chronic Wound Healing Composition", application number: 108144823.

In May 2020, MedS probiotic capsule products were produced.

In March 2021, the registered business address was changed to "13F, No. 297, Section 2, Dongmen Road, East District, Tainan City".

In November 2021 "Chronic Wound Healing Composition" Patent No.: I744735

In December 2021 Cash capital increase with a capital of 20,410,000. Chairman election, the new chairman is HSU-EN, LO.

In March 2022, 11,641,000 shares were issued.

In May 2022 The non-physical issuance of securities has been completed in accordance with the "Regulations on the Operation of Centralized Depository Books for Marketable Securities", and the start date is May 11, 2011.